Beckman Coulter Inc

Beckman Coulter — Q3 2009 Earnings Presentation

16 slides from Beckman Coulter's earnings presentation, Oct 29, 2009

  1. Slide 1: Beckman Coulter Q3 2009 Financial Presentation

    1 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation Scott Garrett Chairman, President & Chief Executive Officer Exhibit 99.2

  2. Slide 2: Key Points Q3 2009

    Key Points Q3 2009 Core Business (ex. ODS) performing well: #1 - Recurring Revenue: 7.7% (cc) #2 - Cash Instrument Sales: 15% (cc) #3 - Operating Income Margin: 13.5% #4 - Expanded Earnings and Cash Flow EPS: $0.95 Free Cash Flow YTD: > $180M

  3. Slide 3: Strength in Diagnostics - Recurring Revenue

    Strength in Diagnostics- ex ODS 8.4% (cc) AutoChemistry and Immunoassay growing above market Access Immunoassay growing >10% (cc) Recurring Revenue: Q3 2009 ($ millions) Product Area Beckman Coulter Olympus Diagnostics (ODS) Consolidated Total Recurring Revenue % Chg in constant currency $620.2 7.7%

  4. Slide 4: Cash Instrument Sales

    Deferred instrument renewals Weakness in Cellular and Life Science Prior year comparables Challenging economic environment Cash Instrument Sales: Q3 2009 ($ millions) Product Area Beckman Coulter Olympus Diagnostics (ODS) Consolidated Total Cash Instrument Sales % Chg in constant currency $137.5 (14

  5. Slide 5: Revenue by Geography

    Revenue by Geography: Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated United States % Chg $381.0 1.2% $21.2 $402.2 6.8% International % Chg in constant currency $376.8 4.4% $43.9 $420.6 16.2% United States: Recurring revenue growing mid-single digits Life Science 7% Inter

  6. Slide 6: Olympus Integration

    Olympus Integration Progress to Date Integration is meeting expectations 2010 Anticipated Synergies: $50 to $60M R&D: $20M Discontinued Immunoassay R&D Selling Expense: $25M Eliminated redundancies to achieve 2010 run rate by year-end General and Admin.: $5-15M Still working through transition servi

  7. Slide 7: Financial Presentation - Charlie Slacik, CFO

    7 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation Charlie Slacik SVP & Chief Financial Officer

  8. Slide 8: 2009 Outlook

    2009 Outlook- (ex ODS) Provided 10/29/09 Total revenue: Reported Flat Constant currency 0% to 2% Recurring revenue (cc) 6% to 7% Op income margin ~13% Non-Operating expense ~ $55 M Tax rate ~ 25% CAPEX ~ $325 M Depreciation & Amortization $270 to $290 M EPS (based on ~ 65.5M shares) $3.85 to $3.95 O

  9. Slide 9: Adjusted P & L

    Adjusted P & L: Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated Revenue: Recurring revenue % Chg in constant currency Cash instrument sales % Chg in constant currency TOTAL % Chg in constant currency $620.2 7.7% 137.5 (14.8%) $757.7 2.8% $55.9 9.2 $65.1 $676.1 17.3% 146.7

  10. Slide 10: Adjusted Non-Op

    Adjusted Non-Op*: Q3 2009 ($ millions) Q3 2009 Q3 2008 Change Interest Income ($1.4) ($2.4) ($1.0) Interest Expense $21.9 $16.7 ($5.2) Misc Non-Op $0.0 ($2.0) ($2.0) Total $20.5 $12.3 ($8.2) * Excludes Olympus Acquisition related currency gains

  11. Slide 11: Adjusted P & L: YTD

    Adjusted P & L: YTD Q3 2009 ($ millions) Beckman Coulter Olympus Diagnostics (ODS) Consolidated Revenue: Recurring revenue % Chg in constant currency Cash instrument sales % Chg in constant currency TOTAL % Chg in constant currency $1,822.9 6.8% 383.0 (20.1%) $2,205.9 0.9% $55.9 9.2 $65.1 $1,878.8 1

  12. Slide 12: Balance Sheet & Cash Flow

    Balance Sheet & Cash Flow YTD Q3 2009 CAPEX: $18M Increase in PP&E CAPEX offset by decrease in OTL CAPEX DSO (ex ODS): 4 day improvement Inventory turns (ex ODS): 3.0 to 3.1 (cc) Adjusted EBITDA TTM: $675M 12% Operating cash flow: $158M to $402M YTD Free cash flow > $180M YTD

  13. Slide 13: Beckman Coulter Q3 2009 Financial Presentation

    13 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation

  14. Slide 14: Concluding Remarks

    Concluding Remarks YTD Q3 2009 Recurring revenue*: 6.8% (cc) Adjusted operating expense*: 3% (cc) Olympus update: Rationale: Reach into high-volume labs, extending cross-selling Integration: Synergies on plan 2010 preliminary outlook, including Olympus, on December 17, 2009 at our Annual Business Re

  15. Slide 15: Beckman Coulter Q3 2009 Financial Presentation

    15 BEC Q3 2009 Conf Call & Beckman Coulter Q3 2009 – Financial Presentation

  16. Slide 16: Forward-Looking Statements and Non-GAAP Financial Information

    Forward-Looking Statements and Non-GAAP Financial Information This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements expectat

Beckman Coulter — Q3 2009 Earnings Presentation on 6ix